450
Participants
Start Date
June 10, 2022
Primary Completion Date
May 30, 2026
Study Completion Date
May 30, 2028
Tislelizumab
GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
Placebo
GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
The Affiliated Hospital of Guangdong Medical College, Zhanjiang
Wuzhou Red Cross Hospital, Wuzhou
Guizhou Cancer Hospital, Guiyang
Hunan Cancer Hospital, Changsha
Cancer Hospital of Guizhou Province
OTHER
Hunan Cancer Hospital
OTHER
Wuzhou Red Cross Hospital
OTHER
Affiliated Hospital of Guangdong Medical University
OTHER
Sun Yat-sen University
OTHER